Search

everythinglearnresearchcommunity

for

Search:↓

A 19-year-old concerned about long-term effects of 5AR inhibitors on physical appearance. They have used finasteride and plan to try dutasteride or RU58841; responses suggest improved skin, hair, and confidence.

A 21-year-old with diffuse thinning hair is considering RU58841 due to side effects from topical finasteride and is asking for the lowest effective dose and time to see results from RU58841 users.

Hair loss discussion includes LLLT treatments and a satirical condition called PLLLTS, causing patients to resemble lighthouses and attract moths. Some users express concern about others taking the satire seriously.

Users discussed increasing oral minoxidil from 2.5mg to 5mg for hair regrowth, with some considering higher doses despite potential side effects. They also mentioned using 1mg oral finasteride alongside minoxidil.

Gizzela is unsure about the dosage and frequency of copper peptides and asks if they can be used with Stemoxydine. They seek advice on applying these treatments together.

The user experienced no improvement in hair loss with finasteride and minoxidil but had side effects. They plan to add wounding, scalp massage, vitamin K, and taurine supplements to their regimen and seek feedback on these additions.

The conversation discusses the use of 0.1% latanoprost for hair regrowth, with concerns about cost and dependency. The user currently uses dutasteride and oral minoxidil and is considering adding latanoprost to their regimen.

User started using topical spironolactone on scalp and face, experienced fever feeling and sluggishness. Asks if side effects are normal or systemic.

Combining minoxidil 5%, tazarotene 0.1% cream, and lumigan for hair loss treatment is discussed. The conversation focuses on the safety and effectiveness of using these treatments together.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

The user is concerned about safely using RU58841 around cats and wonders if applying it 2 hours before a shower is as effective as leaving it overnight. The discussion focuses on the absorption time and effectiveness of RU58841.

A user was prescribed Alpicort E, which contains Estradiol Benzoate, Prednisone, and Salicylic Acid, for hair loss and is seeking others' experiences due to concerns about potential side effects.

An update on the use of Pyrilutamide, a new drug for hair loss, which has resulted in no shedding or testicle ache; other users have questioned the science behind this and shared their own experiences with Finasteride, Minoxidil, and microneedling.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.

A user asked if they can crush caffeine and melatonin tablets to add to their minoxidil solution. Another user sarcastically suggested adding rat poison.

The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.

A 16 year old's experience with using pyrilutamide to treat hair loss, and the potential side effects of adding tretinoin to minoxidil and finasteride treatments.

The conversation discusses the use of pyrilutamide for hair loss, specifically its impact on shedding. The user is inquiring if others have experienced increased or decreased shedding after starting pyrilutamide.

The user is on their 5th week of using pyrilutamide for hair loss without experiencing side effects and has noticed slight hair growth. They also use minoxidil with finasteride and dutasteride as part of their treatment regimen.

The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.

Hair loss discussion includes treatments Min, Fin, and RU. Kintor's KX-826 Phase 2 data release delayed to September due to COVID.

A user is experiencing worsening hair loss despite using 2.5mg Dutasteride, RU58841, and Minoxidil daily for over 8 months. They are concerned that daily nicotine from vaping might be counteracting the treatments.

Oral minoxidil is more effective than topical minoxidil for hair regrowth but may cause side effects like heart issues and increased body hair. Combining it with finasteride is common for better results, though side effects vary.

OP mixed RU58841 with minoxidil and noticed undissolved particles. They are seeking advice on whether it matters or how to fully dissolve it.

Combining minoxidil, pyrilutamide, and copper peptide is questioned, with advice to apply them separately to avoid reactions. Finasteride and minoxidil are recommended for effectiveness.

The user maintained hair with minoxidil, alfatradiol, and fluridil after stopping finasteride due to erectile dysfunction. They recently added pyrilutamide and are seeking feedback on its effectiveness after six months of use.

Treatment for hair loss, including Pyrilutamide, Minoxidil, Finasteride, and RU58841; with some users reporting success in growing vellus hairs.

The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.

Minoxidil's effectiveness varies due to genetic differences in the SULT1A1 enzyme, affecting how well it converts to its active form, minoxidil sulfate. Hyper-responders may experience rapid hair growth and increased side effects, such as pericardial effusion, even at low doses.